Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 401 to 450 of 646 results for diabetes

  1. Fertility problems: assessment and treatment (CG156)

    This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.

  2. Happy Mum Healthy Bump

    in 2015; For the mother – increased risk of miscarriage, gestational diabetes and perinatal complications For the foetus – increased...

  3. Patient group directions (MPG2)

    This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.

  4. YOURmeds for medication support in long-term conditions (MIB289)

    NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .

  5. Everolimus for preventing organ rejection in liver transplantation (TA348)

    Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.

  6. Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures (IPG623)

    Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures in adults. This involves using an ultrasound probe on the skin at the site of the fracture.

  7. Caesarean birth (QS32)

    This quality standard covers the care of pregnant women or pregnant people who are considering having or may need to have a caesarean birth, including those who have had a caesarean birth in the past. It includes decision making, reducing the risk of complications and care after a caesarean birth. It describes high-quality care in priority areas for improvement.

  8. Ticagrelor for the treatment of acute coronary syndromes (TA236)

    Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.

  9. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)

    Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.

  10. Antenatal and postnatal mental health: clinical management and service guidance (CG192)

    This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year. It covers depression, anxiety disorders, eating disorders, drug- and alcohol-use disorders and severe mental illness (such as psychosis, bipolar disorder and schizophrenia). It promotes early detection and good management of mental health problems to improve women’s quality of life during pregnancy and in the year after giving birth.

  11. How do financial factors (including incentives, pricing and taxation of food and incentives, and pricing for physical activity opportunities) affect food and physical activity choices?

    None. Source guidance details Comes from guidance Type 2 diabetes prevention: population and community-level interventions Number

  12. Prescribing guidelines for patients with a first episode psychosis

    people. Psychosis affects 1-3% of the population, which is higher than diabetes in young people. A patients' experience of medication in...

  13. Robot-assisted kidney transplant (IPG609)

    Evidence-based recommendations on robot-assisted kidney transplant in adults. This involves the surgeon using a robot to help with a kidney transplant.

  14. NICE recommends further research to investigate the clinical effectiveness of the integrated sensor-augmented insulin pump therapy systems in younger children and pregnant women. No data are currently available for these subgroups and their inclusion in future studies is encouraged.

    sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo system and the Vibe...

  15. Atrial fibrillation (QS93)

    This quality standard covers identifying and managing atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  16. LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)

    NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .

  17. Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

    Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

  18. Prevention strategies for Charcot arthropathy:- What strategies may be useful in the prevention of Charcot arthropathy?

    would monitor and evaluate the rates of Charcot arthropathy resulting from diabetes, rates and extent of amputation (major or minor),...

  19. Swallowable gastric balloon capsule for weight loss (IPG684)

    Evidence-based recommendations on swallowable gastric balloon capsules for weight loss in adults. This involves swallowing a capsule containing a balloon that is then filled with liquid to inflate it in the stomach.

  20. Service Evaluation for Group Clinics for New Patients with newly Diagnosed Coeliac Disease

    From previous research in patient cohorts receiving treatment for diabetes and obesity, it has been demonstrated that a group clinic...

  21. Diabetic ulcer dressings:- What is the clinical effectiveness of different dressing types in treating diabetic foot problems?

    would monitor and evaluate the cure rates of foot ulcer resulting from diabetes, rates and extent of amputation (major or minor),...

  22. Intensive monitoring for people at risk of diabetic foot problems:- Does intensive monitoring of people at risk of diabetic foot disease reduce the morbidity associated with developing the disease and is such monitoring cost effective?

    monitor and evaluate the rates of foot ulcer or infection resulting from diabetes, rates and extent of amputation (major or minor),...

  23. Project CARE: Supporting people with a positive diagnosis of COVID-19 and reaching out to those in vulnerable groups

    cardiovascular disease, cancer, hypertension, respiratory conditions and diabetes appear to be at a higher risk of developing...

  24. Dupilumab for treating severe asthma with type 2 inflammation (TA751)

    Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.

  25. Hand allotransplantation (IPG383)

    Evidence-based recommendations on hand transplant surgery (allotransplantation). This involves transplanting a hand from a recently deceased donor onto the amputated stump.

  26. Granulox for managing chronic non-healing wounds (MIB296)

    NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .

  27. Sunlight exposure: risks and benefits (NG34)

    This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.

  28. Behaviour change: individual approaches (PH49)

    This guideline covers changing health-damaging behaviours among people aged 16 and over using interventions such as goals and planning, feedback and monitoring, and social support. It aims to help tackle a range of behaviours including alcohol misuse, poor eating patterns, lack of physical activity, unsafe sexual behaviour and smoking.

  29. Sebelipase alfa for treating Wolman disease (HST30)

    Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.

  30. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.

  31. Intravascular lithotripsy for calcified arteries in peripheral arterial disease (IPG780)

    Evidence-based recommendations on intravascular lithotripsy for calcified arteries in peripheral arterial disease. This involves using pressure waves to soften arterial plaque and widen the artery to improve blood flow.

  32. Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis (CG95)

    This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made. It aims to improve outcomes by providing advice on tests (ECG, high-sensitivity troponin tests, multislice CT angiography, functional testing) that support healthcare professionals to make a speedy and accurate diagnosis.

  33. Further research is needed on the benefits and consequences of detecting preclinical diabetic peripheral neuropathy.

    not possible. Such a study could also define the benefits to people with diabetes of improved access to DPN diagnostic and treatment...

  34. What is the most effective management strategy for preventing the development of excessive weight gain and metabolic syndrome associated with the use of antipsychotic medication in children and young people?

    and poor physical health (smoking, lack of exercise) leading to type 2 diabetes and metabolic syndrome are major sources of morbidity...

  35. Bedwetting in children and young people (QS70)

    This quality standard covers assessing and managing bedwetting (nocturnal enuresis) in children and young people (aged 18 and under). It describes high-quality care in priority areas for improvement.

  36. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

  37. Healthy Living Dentistry

    • Commit to promote 6 health campaigns: National Smile Month, National Diabetes Week, Stoptober, Mouth Cancer Awareness Action Month,...

  38. The scarred liver project: a new diagnostic pathway to detect chronic liver disease across primary and secondary care

    Identification of individuals exposed to risk factors namely hazardous alcohol, diabetes and obesity. It utilises validated diagnostics...

  39. A dietetic-led coeliac service incorporating group education

    results and co-existing conditions that may require additional advice (e.g. diabetes mellitus, osteoporosis, lactose intolerance)...

  40. Hyperhidrosis: oxybutynin (ES10)

    Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

  41. What is the effectiveness of awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher oxygen needs?

    aids)• comorbidities (chronic obstructive pulmonary disease, hypertension, diabetes, coronary heart disease, chronic kidney disease,...

  42. Immunosuppressive therapy for kidney transplant in adults (TA481)

    Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).

  43. Developing a 3Ds Clinical Framework in a Community Integrated Team

    health issues including high blood pressure, heart disease, stroke and diabetes. We recognised that patients referred to the...

  44. Medicines Optimisation Peer Review Programme - engaging GP practices to deliver medicines optimisation and implement NICE guidance

    addressed prescriber knowledge gaps e.g. reviewing the effectiveness of newer diabetes medications to ensure cost-effective prescribing...

  45. Fetal monitoring in labour (NG229)

    This guideline covers methods for monitoring the wellbeing of the baby during labour. It includes risk assessment to determine the appropriate level of fetal monitoring, using clinical assessment in addition to fetal monitoring, and interpreting and acting on monitoring findings.

  46. EpiFix for chronic wounds (MIB139)

    NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .

  47. Overprescribing of rivaroxaban in non-atrial fibrillation patients in primary care

    hypertension/previous stroke or transient ischaemic attack, age 75 years or diabetes mellitus. 20mg once daily (NICE TA256) Prophylaxis...

  48. Implantation of an opaque intraocular lens for intractable double vision (IPG293)

    Evidence-based recommendations on implantation of an opaque intraocular lens for intractable double vision. This involves replacing the clear lens of one eye with a non-transparent one to block out one of the double images.

  49. Secondary prevention after a myocardial infarction (QS99)

    This quality standard covers preventing further cardiovascular disease after a myocardial infarction (heart attack). It includes assessment and cardiac rehabilitation. It describes high-quality care in priority areas for improvement.

  50. DuraGraft for preserving vascular grafts (MIB184)

    NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .